GLAXOSMITHKLINE

Human Genome Sciences Inc , which rebuffed an unsolicited $2.6 billion takeover bid by British drugmaker GlaxoSmithKline , said on Tuesday it was reviewing strategic alternatives, including the sale of the company.

AstraZeneca has agreed to buy U.S. company Ardea Biosciences for $1.26 billion, giving it a new gout drug to bolster its weak pipeline in a deal that feeds a wave of M&A in the biotechnology sector.

Human Genome Sciences has rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline, marking a new takeover battle in a drugs sector swept by M&A activity recently.

Human Genome Sciences Inc has rejected an unsolicited bid worth around $2.6 billion from long-time partner GlaxoSmithKline Plc, marking a new takeover battle in a drugs sector that has been swept by M&A recently.

Human Genome Sciences Inc said on Thursday its long-time partner GlaxoSmithKline Plc had made an unsolicited proposal to buy it for $13.00 per share in cash, a move underscoring the rapid pace of deal-making in pharmaceuticals.

The pharmaceutical industry is paying close attention to a case that could determine if about 90,000 sales representatives are entitled to overtime pay.

The top after-market NASDAQ gainers Friday were: Cornerstone OnDemand, TASER International, MAP Pharmaceuticals, Affymax, Avis Budget Group and Steel Dynamics. The top after-market NASDAQ losers were: Pacific Biosciences of California, Targacept, Ancestry.com, Theravance, Vocus and Commercial Vehicle Group.

James Murdoch has severed all ties with News Corp's British newspaper business, which is at the centre of multiple investigations over phone and computer hacking and bribery, according to regulatory filings.

Britain's largest drugmaker GlaxoSmithKline announced on Thursday plans to invest £500 million ($792 million) in local manufacturing operations, opening a facility in Scotland that is expected to create 1,000 jobs over the coming years.

Stock index futures pointed to a higher open on Wall Street on Wednesday, with futures for the S&P 500 up 0.4 percent, Dow Jones futures up 0.2 percent and Nasdaq 100 futures also up 0.2 percent at 5 a.m. E.D.T. (0900 GMT)

Many patients taking a widely prescribed class of oral cancer drugs are also using a variety of medications that could reduce the effectiveness of the cancer treatment or increase its toxic side effects, according to research by Medco Health Solutions Inc.

Europe is undermining drug innovation by cutting prices, raising barriers to new medicines and freeloading off others in Asia and the United States who are more willing to pay, the boss of Pfizer, the world's largest drugmaker, said.

A research group is proposing a new tool in the fight against drug-resistant bacteria: turn infections into a rare disease.

Daiichi Sankyo Co. and GlaxoSmithKline have stated that they have agreed to form a 50-50 joint venture which will bring new products to the Japanese market.

As the Qnexa weight-loss pill awaits approval by the FDA, here's a list of five non-dieting meds people take to cut fat. Warning: these prescription medications are meant to be used to address other issues, but they have been proven in studies to also help people drop pounds.

Experimental obesity drug Qnexa won the backing of U.S. health advisors on Wednesday, raising hopes for approval of the first prescription weight-loss pill in 13 years.

Experimental obesity drug Qnexa won the backing of U.S. health advisors on Wednesday, raising hopes for approval of the first prescription weight-loss pill in 13 years.

The weightloss drugs like GlaxoSmithKline's Alli and Roche's Xenical run the risk of very rare liver-related side effects, according to European Medicines Agency.

Weakness in banks and commodity stocks dragged Britain's leading share index lower on Monday as the protracted search for a Greek bond deal and concerns about economic growth kept investors nervous.

The world's major pharmaceutical companies joined forces with governments and leading global health organizations Monday to donate drugs and scientific know-how to help control or wipe out 10 neglected tropical diseases by 2020.

Whistle-blowers earned more than $532 million in 2011 through lawsuits alleging fraud against the U.S. government, a record for such payouts, according to a law-firm study published on Friday.